Review shows neoadjuvant stereotactic radiosurgery enhances local control in brain metastases, indicating its potential benefit over traditional approaches.
Key Points
Neoadjuvant SRS aims to improve local tumor control in brain metastases while reducing risks of leptomeningeal dissemination.
Recent studies indicate that neoadjuvant SRS offers comparable or superior local control rates compared to postoperative SRS, with lower radiation toxicity.
Uncertainties remain regarding optimal dosing and patient selection criteria, as factors like tumor size and histology can influence outcomes.
Further investigation is needed to assess the long-term efficacy of neoadjuvant SRS and its integration with systemic therapies.